Edward D Huey1, Rachel Fremont1, Masood Manoochehri1, Yunglin Gazes1, Seonjoo Lee1, Stephanie Cosentino1, Michael Tierney1, Eric M Wassermann1, Parastoo Momeni1, Jordan Grafman1. 1. Taub Institute for Research on Alzheimer's Disease and the Aging Brain, New York (Huey, Manoochehri, Gazes, Cosentino); Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York (Huey, Fremont); Department of Neurology, College of Physicians and Surgeons, Columbia University, New York (Huey, Manoochehri, Gazes, Cosentino); Department of Biostatistics, Mailman School of Public Health, Columbia University, New York (Lee); Cognitive Neuroscience Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Md. (Huey, Tierney, Wassermann, Grafman); RONA Holdings, Silicon Valley, Calif. (Momeni); and Cognitive Neuroscience Laboratory, Think and Speak Lab, Shirley Ryan AbilityLab, Chicago (Grafman).
Abstract
OBJECTIVE: The authors examined the effects of two common functional polymorphisms-brain-derived neurotrophic factor (BDNF) Val66Met and catechol-O-methyltransferase (COMT) Val158Met-on cognitive, neuropsychiatric, and motor symptoms and MRI findings in persons with frontotemporal lobar degeneration (FTLD) syndromes. METHODS: The BDNF Val66Met and COMT Val158Met polymorphisms were genotyped in 174 participants with FTLD syndromes, including behavioral variant frontotemporal dementia, primary progressive aphasia, and corticobasal syndrome. Gray matter volumes and scores on the Delis-Kaplan Executive Function System, Mattis Dementia Rating Scale, Wechsler Memory Scale, and Neuropsychiatric Inventory were compared between allele groups. RESULTS: The BDNF Met allele at position 66 was associated with a decrease in depressive symptoms (F=9.50, df=1, 136, p=0.002). The COMT Val allele at position 158 was associated with impairment of executive function (F=6.14, df=1, 76, p=0.015) and decreased bilateral volume of the head of the caudate in patients with FTLD (uncorrected voxel-level threshold of p<0.001). Neither polymorphism had a significant effect on motor function. CONCLUSIONS: These findings suggest that common functional polymorphisms likely contribute to the phenotypic variability seen in patients with FTLD syndromes. This is the first study to implicate BDNF polymorphisms in depressive symptoms in FTLD. These results also support an association between COMT polymorphisms and degeneration patterns and cognition in FTLD.
OBJECTIVE: The authors examined the effects of two common functional polymorphisms-brain-derived neurotrophic factor (BDNF) Val66Met and catechol-O-methyltransferase (COMT) Val158Met-on cognitive, neuropsychiatric, and motor symptoms and MRI findings in persons with frontotemporal lobar degeneration (FTLD) syndromes. METHODS: The BDNF Val66Met and COMT Val158Met polymorphisms were genotyped in 174 participants with FTLD syndromes, including behavioral variant frontotemporal dementia, primary progressive aphasia, and corticobasal syndrome. Gray matter volumes and scores on the Delis-Kaplan Executive Function System, Mattis Dementia Rating Scale, Wechsler Memory Scale, and Neuropsychiatric Inventory were compared between allele groups. RESULTS: The BDNF Met allele at position 66 was associated with a decrease in depressive symptoms (F=9.50, df=1, 136, p=0.002). The COMT Val allele at position 158 was associated with impairment of executive function (F=6.14, df=1, 76, p=0.015) and decreased bilateral volume of the head of the caudate in patients with FTLD (uncorrected voxel-level threshold of p<0.001). Neither polymorphism had a significant effect on motor function. CONCLUSIONS: These findings suggest that common functional polymorphisms likely contribute to the phenotypic variability seen in patients with FTLD syndromes. This is the first study to implicate BDNF polymorphisms in depressive symptoms in FTLD. These results also support an association between COMT polymorphisms and degeneration patterns and cognition in FTLD.
Authors: Naomi Kouri; Melissa E Murray; Anhar Hassan; Rosa Rademakers; Ryan J Uitti; Bradley F Boeve; Neill R Graff-Radford; Zbigniew K Wszolek; Irene Litvan; Keith A Josephs; Dennis W Dickson Journal: Brain Date: 2011-09-20 Impact factor: 13.501
Authors: José A Apud; Venkata Mattay; Jingshan Chen; Bhaskar S Kolachana; Joseph H Callicott; Roberta Rasetti; Guilna Alce; Jennifer E Iudicello; Natkai Akbar; Michael F Egan; Terry E Goldberg; Daniel R Weinberger Journal: Neuropsychopharmacology Date: 2006-10-25 Impact factor: 7.853
Authors: Giuseppe Blasi; Venkata S Mattay; Alessandro Bertolino; Brita Elvevåg; Joseph H Callicott; Saumitra Das; Bhaskar S Kolachana; Michael F Egan; Terry E Goldberg; Daniel R Weinberger Journal: J Neurosci Date: 2005-05-18 Impact factor: 6.167
Authors: Venkata S Mattay; Terry E Goldberg; Francesco Fera; Ahmad R Hariri; Alessandro Tessitore; Michael F Egan; Bhaskar Kolachana; Joseph H Callicott; Daniel R Weinberger Journal: Proc Natl Acad Sci U S A Date: 2003-04-25 Impact factor: 11.205
Authors: F Miyajima; W Ollier; A Mayes; A Jackson; N Thacker; P Rabbitt; N Pendleton; M Horan; A Payton Journal: Genes Brain Behav Date: 2007-10-31 Impact factor: 3.449
Authors: P M Butler; W Chiong; D C Perry; Z A Miller; E D Gennatas; J A Brown; L Pasquini; A Karydas; D Dokuru; G Coppola; V E Sturm; A L Boxer; M L Gorno-Tempini; H J Rosen; J H Kramer; B L Miller; W W Seeley Journal: Neuroimage Clin Date: 2019-04-10 Impact factor: 4.881